J Neurosci 2005 May;25(18):4593-604
Department of Psychology, Washington University in St. Louis, St. Louis, Missouri 63130-4899, USA.
Download full-text PDF
Indian Heart J 2018 Jul 30;70 Suppl 1:S90-S95. Epub 2018 Apr 30.
Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, NY, United States.
Background: Hemodynamic support with Impella (Abiomed Inc., Danvers, MA) devices is becoming a more prevalent treatment option for patients with cardiogenic shock (CS) undergoing percutaneous coronary intervention (PCI). There exists only limited published data regarding outcome differences between male and female patients. Read More
Oncotarget 2018 May 1;9(33):23253-23263. Epub 2018 May 1.
Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan.
Although the oncogene MMSET (also known as NSD2 or WHSC1) has an essential role in malignancies, its impact on human endometrial cancer (EC) metastasis and the molecular mechanism of MMSET regulation are largely unknown. We report that MMSET was markedly upregulated in EC cell lines and EC tissues, and was significantly associated with poor survival in EC. MMSET overexpression greatly promoted EC cell invasion and sphere formation, whereas inhibition of MMSET reduced EC cell invasion and sphere formation. Read More
Iran J Kidney Dis 2018 03;12(2):107-111
Departement of Pediatrics, Faculty of Medicine, Beni-Suef University, Egypt.
Introduction: Early diagnosis of minimal change disease (MCD) is challenging in nephrotic children. CD80 is a protein expressed on the surface of podocytes associated with nephrotic syndrome and it is implicated in the induction of proteinuria. This study aimed to investigate the use of urinary CD80 for the diagnosis of MCD. Read More
Lancet Oncol 2017 12;18(12):e731-e741
Department of Haematology-Oncology, National University Cancer Institute, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore. Electronic address:
Use of immune checkpoint inhibitors targeting the programmed cell death protein-1/programmed cell death-ligand 1 and cytotoxic T lymphocyte-associated protein-4 axes has yielded impressive results in some clinical trials. However, only a subset of patients initially respond to these inhibitors, and increasing clinical evidence indicates that a substantial proportion of initial responders ultimately relapse with lethal, drug-resistant disease months or years later. Studies that have used massively parallel sequencing have shed light on the rich functional landscape of mutations that endow tumour cells with the ability to evade T-cell-mediated immunosurveillance. Read More
AIDS 2017 07;31(12):1653-1663
aPuerta de Hierro Research Institute, Majadahonda, Madrid bHospital Vall d'Hebrón, Barcelona cHospital de Conxo-CHUS, Santiago de Compostela dClinic University Hospital, Valladolid eBlood and Tissue Bank, Barcelona fRegional Transfusion Center, Madrid gCentro de Hemoterapia de Castilla-León, Valladolid hHospital Miguel Servet, Zaragoza iHospital Clínico Universitario Lozano Blesa, Zaragoza jUniversity Clinic kComplejo Hospitalario, Pamplona lCentro Sanitario Sandoval, Madrid mCristal-Piñor Hospital, Orense nGeneral Hospital, Alicante oHospital Virgen del Rocío, CIBERESP, Seville pRio Ortega Hospital, Valladolid qLa Paz University Hospital, Autonomous University, Madrid, Spain.
: Human T-lymphotropic virus type 1 (HTLV-1) infection is a neglected disease despite roughly 15 million people are chronically infected worldwide. Lifelong less than 10% of carriers develop life-threatening diseases, mostly a subacute myelopathy known as tropical spastic paraparesis (TSP) and a lymphoproliferative disorder named adult T-cell leukemia (ATL). HTLV-1 is efficiently transmitted perinatally (breastfeeding), sexually (more from men to women) and parenterally (transfusions, injection drug user (IDU), and transplants). Read More